Home/Pipeline/TILT-123 (igrelimogene litadenorepvec)

TILT-123 (igrelimogene litadenorepvec)

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

TILT Biotherapeutics

About TILT Biotherapeutics

TILT Biotherapeutics is a Finnish-American biotech pioneering oncolytic immunotherapies to treat solid tumors. Its core TILT® technology platform utilizes engineered adenoviruses armed with immunostimulatory cytokines, delivered intravenously, to turn 'cold' tumors 'hot' and enhance T-cell therapies. The lead asset, TILT-123, is in Phase I trials in the US and Europe, both as a monotherapy and in combination with checkpoint inhibitors or TIL therapy. The company operates as a private, pre-revenue entity with a team of approximately 20, pursuing a therapeutics business model through internal development and strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active